Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01108042
Other study ID # TISOC-1
Secondary ID 2009-011902-41
Status Completed
Phase Phase 1/Phase 2
First received April 14, 2010
Last updated May 17, 2016
Start date November 2009
Est. completion date February 2016

Study information

Verified date May 2016
Source University of Jena
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

A combination therapy of Docetaxel, Cisplatin und 5-Fluorouracil (= TPF) will be used in patients with resectable oropharyngeal and cavity of the mouth cancer. To improve the compatibility of the TPF-induction without decreasing the efficacy the dose will be given on day 1 and 8 instead of applying the whole dose on day 1 every 3 weeks.

In the phase I-part of the trial the optimal therapeutic dose of Docetaxel and Cisplatin will be defined.

In the phase II-part the progression-free survival after 2 years will be assessed in patients treated with the optimal therapeutic dose.


Description:

Local advanced Oropharyngeal and cavity of the mouth Cancer are often treated with a combination of surgery and/or radiation and /or chemotherapy.

Despite of therapy improvement there are only little advances in progression-free survival and overall survival.

Therefore new therapy concepts are needed. The advantage of the induction chemotherapy is the possibility of tumor response assessment during chemotherapy and may present a selection criterion for organ preservation.

In order to minimize the time between chemotherapy and surgery it is important to have an early answer for the tumor response. In this study response will be assessed after the first cycle of chemotherapy. Patients showing no tumor response will be operated at once. The other patients will receive further cycles of chemotherapy.

Toxicity of the induction chemotherapy have to be moderate because surgery should not be delayed.

To improve the tolerance of induction therapy the medication dose isn't given on day 1 every 3 weeks, but is dispersed on day 1 and day 8, q3weeks.


Recruitment information / eligibility

Status Completed
Enrollment 71
Est. completion date February 2016
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Histological proven, resectable squamous epithelial carcinoma of the oropharynx and the cavity of the mouth

2. R0-resection possible

3. All T N2 M0 / all T N3 M0 / if T3 or T4a also N0-1 M0

4. Leucocytes > 4000/mm³ bzw. neutrophils > 2000/mm³, thrombocytes > 100000/mm³

5. adequate kidney function, defined as serum creatinine und urea in normal range, Creatinine clearance > 60 ml/min

6. adequate liver function with glutamate oxaloacetate transaminase (SGOT), glutamate pyruvate transaminase (SGPT) and bilirubin in normal range

7. electrolytes in normal range

8. risks of anesthesia complications normal or minor increased

9. Eastern Cooperative Oncology Group (ECOG) 0-2 / Karnofsky >= 60%

10. Age 18 - 80 years

11. signed written informed consent

12. effective contraception for both male and female subjects if the risk of conception exists

Exclusion Criteria:

13. T1 N0 M0 / T1 N1 M0 / T2 N0 M0 / T2 N1 M0

14. Resection without curative intention: primary tumor is not treatable with resection methods

15. Infiltration of the lower jaw

16. M1 status

17. Tumor not measurable with Innovation Center Computer Assisted Surgery (ICCAS) methods

18. No prior chemotherapy or radiation (a primary surgery is allowed)

19. Metachronous or oder synchronous malignoma (Exception: basal cell carcinoma)

20. Life expectance < 3 months

21. ECOG > 2; Karnofsky < 60%

22. acute infections or fever

23. known HIV-infection or other immune suppression

24. severe cardio pulmonary concomitant diseases

25. chronic disease with continuous therapy (uncontrolled diabetes, rheumatoid arthritis) especially continuous therapy with steroids

26. other concomitant diseases which, in the investigator's opinion, would exclude the patient from the study

27. Contraindications which permit a therapy with Docetaxel, Cisplatin, 5-FU or radiation therapy

28. missing patient's compliance

29. regular Follow-up visits not possible

30. Pregnancy or lactation period

31. legal incapacity or limited legal capacity

32. Participation in another clinical trial or administration of a not approved substance within 30 days before registration

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Taxotere, Cisplatin, 5-Fluorouracil (5-FU)
Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out. Phase 2: Optimal dose of phase 1 will be given.

Locations

Country Name City State
Germany Städt. Kliniken Bielefeld gem. GmbH Bielefeld
Germany Friedrich-Schiller-University Jena Jena
Germany Universitätsklinikum Leipzig - Klinik und Poliklinik für HNO-Heilkunde Leipzig
Germany Klinikum Ernst von Bergmann Potsdam

Sponsors (1)

Lead Sponsor Collaborator
Orlando Guntinas-Lichius, Prof. Dr. med.

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determination of progression-free survival after 2 years 24 months No
Secondary Overall survival after 2 years after 2 years No
Secondary Determination of the efficacy of the induction therapy CT or magnetic resonance tomography (MRT) of the neck region after 1, 12 and 24 months No
Secondary Function of swallowing according the penetration-aspiration-scale assessed according the penetration-aspiration-scale (PAS, Rosenbek et al. 1996) and according measuring after Prosiegel (Prosiegel et al. 2002). 0,1, 6, 12, 18, 24 months Yes
Secondary Adverse events as a measure of safety and tolerability The number of patients with adverse events will be evaluated. Adverse events will be assessed according Common Terminology Criteria of Adverse Events (CTCAE) v.3.0 and analysed as number per patient and number per cycle. once a week Yes
Secondary Quality of life European Organisation for Research and Treatment of Cancer (EORTC) Quality of life questionnaire (QLQ) for head and neck cancer patients (HN35) questionnaire filled in by the patients 0,1, 6, 12, 18, 24 months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04444869 - Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer Phase 2
Completed NCT00158678 - IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Phase 3
Completed NCT04567082 - Proteome- and Methylation Profiles in Oropharyngeal Cancer
Recruiting NCT06016699 - Immunological Function After Radiation With Either Proton or Photon Therapy
Withdrawn NCT04001413 - Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients Phase 2
Completed NCT03435471 - Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer N/A
Completed NCT05055206 - Study of Lymphatic Drainage Mapping in Oropharyngeal Cancers N/A
Recruiting NCT04359199 - QUantitative Assessment of Swallowing After Radiation (QUASAR)
Recruiting NCT05793151 - Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy N/A
Active, not recruiting NCT02908477 - Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer Phase 3
Active, not recruiting NCT00232960 - Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC N/A
Completed NCT05698667 - Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer N/A
Recruiting NCT05757817 - Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae N/A
Active, not recruiting NCT02586207 - Pembrolizumab in Combination With CRT for LA-SCCHN Phase 1
Completed NCT03342378 - PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients
Active, not recruiting NCT03416153 - Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer Phase 2
Terminated NCT01066741 - Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer Phase 3
Completed NCT03418792 - Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx N/A
Recruiting NCT06088381 - Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) Phase 2
Recruiting NCT05686226 - E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers Phase 2